Effectiveness of aldosterone blockade in patients with diabetic nephropathy

Hypertension

Volumn 41, Issue 1, 2003, Pages 64-68

  Sato, Atsuhisa ^a   Hayashi, Koichi ^b   Naruse, Mitsuhide ^c   Saruta, Takao ^b  

^a Mito Red Cross Hospital   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Aldosterone; Angiotensin converting enzyme; Diabetic nephropathy hemodialysis; Hypertrophy; Ventricular function, left

Indexed keywords

ALDOSTERONE ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SPIRONOLACTONE; TRANDOLAPRIL;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; DIABETIC NEPHROPATHY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE MASS; HEMODIALYSIS; HUMAN; HYPERTENSION; LONG TERM CARE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN URINE LEVEL;

ALBUMINURIA; ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; FEMALE; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; SPIRONOLACTONE;

EID: 0037222490     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000044937.95080.E9     Document Type: Article

References (30)

1. Crabbe J. Stimulation of active sodium transport by the isolated toad bladder with aldosterone in vitro. J Clin Invest. 1961;40:2103-2106.
2. Funder JW. Aldosterone, salt and cardiac fibrosis. Clin Exp Hypertens. 1997;19:885-899.
3. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium and myocardial fibrosis. J Lab Clin Med. 1992;120:893-901.
4. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, for the Randomized Aldactone Evaluation Study. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
5. Sato A, Suzuki Y, Shibata H, Saruta T. Plasma aldosterone concentrations are not related to the degree of angiotensin-converting enzyme inhibition in essential hypertensive patients. Hypertens Res. 2000;23:25-31.
6. Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res. 2001;29:13-21.
7. Sato A, Takane H, Saruta T. High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients. Hypertens Res. 2001;24:99-104.
8. Sato A, Suzuki Y, Saruta T. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res. 1999;22:17-27.
9. Epstein M. Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. J Hypertens. 2001;19:829-842.
10. Rocha R, Stier CT Jr, Kifor I, Ochoa-maya MR, Rennke HG, Williams GH, Adler GK. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000;141:3871-3878.
11. Sun Y, Zhang J, Zhang JQ, Ramires FJ. Local angiotensin II and transforming growth factor-beta 1 in renal fibrosis of rats. Hypertension. 2000;35:1078-1084.
12. Grundy SM, Benjamin IJ, Burke GL, Chait A, Ecket RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134-1146.
13. Shiigai T, Shichiri M. Late escape from the antiproteinuric effect of ACE inhibitors in nondiabetic renal disease. Am J Kidney Dis. 2001;37:477-483.
14. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
15. Guidelines Subcommittee. World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens. 1999;1999:17:151-183.
16. Schwab SJ, Christensen RL, Dougherty K, Klahr S. Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. Arch Intern Med. 1987;147:943-944.
17. Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med. 1983;309:1543-1546.
18. American Diabetes Association. Diabetic nephropathy. Diabetes Care. 2002;25:S85-S89.
19. Sahn DJ, DeMaria A, Kisslo J, Weyman A. The Committee on M-Mode Standardization of the American Society of Echocardiography: recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083.
20. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation. 1977;55:613-618.
21. Lijnen P, Staessen J, Fagard R, Amery A. Increase in plasma aldosterone during prolonged captopril treatment. Am J Cardiol. 1982;49:1561-1563.
22. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol. 1981;91:457-465.
23. Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail. 1996;2:47-54.
24. Borghi C, Boschi S, Ambrosioni E, Melandri G, Branzi A, Magnani B. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol. 1993;33:40-45.
25. Tang WHW, Vagelos RH, Yee YG, Benedict CR, Willson K, Liss CL, LaBelle P, Fowler MB. Neurohormonal and clinical responses to highversus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol. 2002;39:70-78.
26. Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Cabrini G, Bonizzato A, Graziani M, Anker SD, Coats AJS, Zardini P. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol. 2001;37:1808-1812.
27. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med. 2001;345:925-926. Letter.
28. Arutyunov G, Chernyavskaya T, Korsunskaya M, Rylova A. Study of the efficacy and safety of RAAS long-term complete blockade in type II diabetic patients with MAU and essential hypertension. Eur Heart J. 2000;21:91. Abstract.
29. Liu YJ, Nakagawa Y, Toya K, Wang Y, Saegusa H, Nakanishi T, Ohzeki T. Effects of spironolactone on systolic blood pressure in experimental diabetic rats. Kidney Int. 2000;57:2064-2071.
30. Sato A, Funder JW. High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes. Endocrinology. 1996;137:4145-4153.